Source: Virtual Congress 2020 – Real-world data and registries of thoracic oncology
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
C. Lips (Berlin, Germany), G. Rafflenbeul (Berlin, Germany), T. Blum (Berlin, Germany), J. Kollmeier (Berlin, Germany), D. Misch (Berlin, Germany), M. Schäfer (Berlin, Germany), S. Stephan-Falkenau (Berlin, Germany), A. Streubel (Berlin, Germany), S. Thiel (Berlin, Germany), T. Mairinger (Berlin, Germany), T. Bauer (Berlin, Germany). Clinical and molecular features of V600E and non-V600E BRAF mutations in NSCLC – a retrospective monocentric observational study. 1689

Member's Comments

No comment yet.

Related content which might interest you: EGFR, KRAS, HER2, BRAF and PI3KCA mutation status in metastatic cancer patients: Thoracic cytological specimens obtained in routine clinical practice Source: Annual Congress 2013 –Progress in bronchoscopy and pathology techniques for diagnosis of thoracic malignancies Year: 2013 EGFR, KRAS, BRAF and ALK gene alterations in lung adenocarcinomas: patient outcome, interplay with morphology and immunophenotype Source: Eur Respir J 2014; 43: 872-883 Year: 2014 Clinical efficacy of 1st line EGFR-TKIs for NSCLC habouring EGFR mutation with high PD-L1 expression; A single-centered retrospective study Source: Virtual Congress 2020 – Prognostic and predictive factors: treatment of lung cancer Year: 2020 KRAS & TP53 mutations cause malignant mesothelioma Source: ERS Lung Science Conference 2017 Year: 2017 KRAS oncogene in lung cancer: focus on molecularly driven clinical trials Source: Eur Respir Rev 2015; 25: 71-76 Year: 2016 Prognostic value of TP53, KRAS and EGFR mutations in nonsmall cell lung cancer: the EUELC cohort Source: Eur Respir J 2012; 40: 177-184 Year: 2012 LSC - 2017 - KRAS & TP53 mutations cause malignant mesothelioma Source: International Congress 2017 – Pleural disease and mesothelioma: from the bench to the bedside Year: 2017 French multicentric validation of ALK rearrangement diagnostic in 547 lung adenocarcinomas Source: Eur Respir J 2015; 46: 207-218 Year: 2015 Outcomes of NSCLC patients with positive EGFR mutation Source: Annual Congress 2012 - Prognosis of lung cancer Year: 2012 Evaluation of gene mutation status and metastasis in lung adenocarcinoma: a multicentric prospective study in Turkey Source: International Congress 2019 – Biology and prognosis of lung cancer Year: 2019 Clinical characteristics of 32 patients with BRAF V600E-mutated lung adenocarcinoma Source: International Congress 2015 – Advances in the therapy of lung cancer Year: 2015 p.Leu747Pro mutation leads to misdiagnosis in EGFR mutation assessment – first Caucasian NSCLC patients reported Source: International Congress 2017 – Gene signatures in bronchial diseases Year: 2017 Are KRAS mutations druggable? Source: New biomarkers, molecules and therapeutic sequences for non small cell lung carcinoma in the era of precision medicine Year: 2019 Cost-effectiveness of KRAS, EGFR and ALK testing for decision making in advanced nonsmall cell lung carcinoma: the French IFCT-PREDICT.amm study Source: Eur Respir J, 51 (3) 1701467; 10.1183/13993003.01467-2017 Year: 2018 Retrospective study of treatment outcomes according to exon difference with EGFR mutations in non-small cell lung cancer patient in Korea Source: Annual Congress 2012 - New biomarkers for lung cancer Year: 2012 Equal efficacy of gefitinib in chemonaive lung adenocarcinoma patients with either exon 19 deletion or L858R point mutation Source: International Congress 2016 – Lung cancer: therapeutic modalities, re-staging, and follow-up Year: 2016 Cytological samples for the study of EGFR, KRAS and ALK mutations in non-small cell lung cancer Source: Annual Congress 2013 –Progress in bronchoscopy and pathology techniques for diagnosis of thoracic malignancies Year: 2013 A detailed immunohistochemical analysis of PI3K/AKT/MTOR pathway in lung cancer: Correlation with PIK3CA, AKT1, K-RAS or PTEN mutational status and clinicopathological features Source: Annual Congress 2013 –Prognostic factors and subtyping of lung cancer Year: 2013 Mapping of KRAS mutations during chemical carcinogenesis Source: Virtual Congress 2020 – Inflammatory pathways in chronic airway diseases Year: 2020 Frequency and clinical-tomographic characterization of NSCLC with T790M mutation to TKI progression. Source: International Congress 2019 – Diagnosis of lung cancer Year: 2019